A plethora of receptors have been reported to be associated with the malignant progression of cancer such as SSTR, integrin, transferrin, HER2, APN, LHRH, EGFR, EpCAM, and CD133, which have been utilized for developing the peptide-based functionalized NDS for targeted cancer therapy as well as diagnosis. This evidence concerns the gene GNRH1 and cancer.